title: Quetiapine for the treatment of cocaine use disorder.
abstract: BACKGROUND
  Cocaine addiction continues to be a significant healthcare issue, yet there are no FDA approved medications for the treatment of cocaine use disorder within the United States.
  
  
  METHODS
  This 12-week, prospective, double-blind, randomized, placebo-controlled study examined the effectiveness of quetiapine (Seroquel XR™) versus matched placebo for the treatment of DSM-IV cocaine dependence in non-psychotic individuals. Subjects randomized to quetiapine (N = 29) were titrated up to a target dose of 400mg/day of quetiapine, while those in the placebo arm (N = 31) were given a matched placebo. All subjects had weekly clinic visits and a cognitive-behavioral therapy group session. Outcome measures included self-report of cocaine use and money spent on cocaine as well as urine drug screens (UDS).
  
  
  RESULTS
  The drop-out rate was substantial at 68%. Logistic regression analysis did not find significant differences between groups in predicting end-of trial abstinence, defined as three consecutive weekly negative UDS (13.7% in the quetiapine group versus 12.9% in the placebo group; p = .92). Based upon a repeated measures analysis of variance, subjects in this study, as a whole, demonstrated reductions in their self-reported use of cocaine, self-reported money spent on cocaine, and number of days per week using cocaine. However, the quetiapine group did not differ significantly from the placebo group.
  
  
  CONCLUSIONS
  This study did not find group differences between the quetiapine and placebo arms, suggesting that quetiapine is not an efficacious treatment for DSM-IV cocaine dependence.
authors: VA Puget Sound Health Care System, American Lake Division (A-116), University of Washington, 9600 Veterans Drive SW, Tacoma, WA 98493, United States. Electronic address: Andre.Tapp@va.gov.
authors: Andre
authors: A
authors: Tapp
authors: VA Puget Sound Health Care System, University of Washington, Tacoma, WA, United States.
authors: Amanda Ernst
authors: AE
authors: Wood
authors: Sheridan VAMC, University of Wyoming, Laramie, WY, United States.
authors: Annette
authors: A
authors: Kennedy
authors: VA Puget Sound Health Care System, University of Washington, Tacoma, WA, United States.
authors: Patrick
authors: P
authors: Sylvers
authors: VA Puget Sound Health Care System, University of Washington, Tacoma, WA, United States.
authors: Nael
authors: N
authors: Kilzieh
authors: VA Puget Sound Health Care System, University of Washington, Tacoma, WA, United States.
authors: Andrew J
authors: AJ
authors: Saxon
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019970:Cocaine-Related Disorders / Q000188:drug therapy* / Q000628:therapy*; D015928:Cognitive Behavioral Therapy / Q000379:methods; D039721:Diagnostic and Statistical Manual of Mental Disorders; D003987:Dibenzothiazepines / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010352:Patient Dropouts / Q000706:statistics & numerical data; D011446:Prospective Studies; D000069348:Quetiapine Fumarate; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D003987:Dibenzothiazepines; D000069348:Quetiapine Fumarate
keywords: Cocaine use disorder; Quetiapine; Treatment trial